STOCK TITAN

Catheter Precision (VTAK) S-1 Filings

VTAK NYSE

Ticker history: VTAK became VJET (Flyte Aviation, Inc.) on .

Here are the S-1 registration statements from Catheter Precision, Inc. (VTAK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-1 covers the registration statement a company files to sell shares publicly, so if you follow VTAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTAK filings page.

Rhea-AI Summary

Catheter Precision, Inc. is registering 68,067,042 shares of common stock for resale by existing investors. These shares include 392,608 already outstanding shares, plus stock issuable from multiple preferred series (C-1, C-2, C-3, D, J) and Series M warrants. The company will receive no proceeds from these sales, while existing holders face very high potential dilution: as of July 2, 2026, only 3,609,471 shares were outstanding, and the prospectus notes that issuance of the covered stock could raise the share count by about 25.3 times and represent roughly 96.2% of post‑issuance shares. The filing also details heavy reliance on recent private placements, significant debt assumed in the FLYTE aviation acquisition, restrictive financing covenants, and an auditor’s substantial doubt about the company’s ability to continue as a going concern.

Rhea-AI Summary

Catheter Precision, Inc. is registering 68,067,042 shares of common stock for resale by existing security holders, and will not receive any proceeds from these stockholder sales. As of June 22, 2026, there were 2,692,473 shares of common stock issued and outstanding.

The registered shares include common stock issued or issuable upon conversion of multiple series of preferred stock and related warrants, as well as shares tied to the acquisition of private aviation company FLYTE and related financings. The company highlights that issuing these shares could significantly increase its outstanding share count and cause substantial dilution to existing holders. The prospectus also notes liquidity pressures, assumed and new debt tied to the FLYTE acquisition, and an auditor statement expressing substantial doubt about the company’s ability to continue as a going concern.